Azienda Sanitaria dell'Alto Adige-Comprensorio sanitario di Bolzano
- Address
- lock Available on a paid plan
Azienda Sanitaria dell'Alto Adige-Comprensorio sanitario di Bolzano
The Azienda Sanitaria dell'Alto Adige-Comprensorio sanitario di Bolzano is a healthcare facility in South Tyrol, Italy, actively engaged in advanced oncology research. The center demonstrates particular expertise in breast cancer treatment and immunotherapy clinical trials, focusing on aggressive subtypes that require innovative therapeutic approaches.
- Triple negative breast cancer adjuvant therapy research
- Anti-PD-L1 immunotherapy clinical trials using Avelumab
- High-risk breast cancer disease-free survival studies
The center's participation in the A-Brave trial reflects its commitment to advancing treatment options for patients with high-risk triple negative breast cancer. The research investigates whether one year of adjuvant treatment with Avelumab, an anti-PD-L1 antibody, can improve disease-free survival following curative-intent treatment including surgery and chemotherapy. This work is particularly significant as triple negative breast cancer represents one of the most challenging breast cancer subtypes, requiring specialized expertise in both surgical oncology and systemic therapy management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria dell'Alto Adige-Comprensorio sanitario di Bolzano
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized Trial of Adjuvant Avelumab in High-Risk Triple Negative Breast Cancer Post-Curative Treatment | Universita Degli Studi Di Padova | Phase III | Not Recruiting | Jun 2016 | Oct 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Avelumab | 1 | Unknown | 2016-06-16 | 2016-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.